AIM ImmunoTech Inc. AIM
0.14 USD -0.02 (-12.10%)
At closeNov 10, 2026, 5:28 PM EST
0.14 0.00 -1.59%
After hours · Nov 10, 5:28 PM ET
0.12 Day range 0.1639
0.12 52-week range 1.82
- YTD
- -87.45%
- 1 year
- -90.92%
News
globenewswire.com AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series OCALA, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will participate in the Webull Corporate Connect Webinar…
marketbeat.com What Aimia (AIM) Said on Its Q3 Earnings Call Aimia TSE: AIM reported higher third-quarter revenue as its Cortland business benefited from price increases and improving demand in several markets, while a write-down on its Clear Media investment…
globenewswire.com AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer New investor presentation outlines scientific rationale for combining Ampligen's immune-stimulating activity with daraxonrasib's targeted RAS inhibition to potentially prolong clinical benefit
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN)…
benzinga.com Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7 Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.- benzinga.com AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of…
benzinga.com AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this…
benzinga.com AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026 At the center of AIM's strategy is Ampligen® (rintatolimod), the Company's proprietary TLR3 agonist immunotherapy, which is being evaluated in the ongoing Phase 2 DURIPANC study in combination with- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com AIM ImmunoTech Commences ~$2.65M Registered Direct Offering Of 2.554M Common Shares At $0.5189/Share AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced…
- benzinga.com AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 Shares This prospectus relates to the offering and resale by the Selling Stockholders listed herein of up to an aggregate of 31,287,933 shares of our common stock, par value $0.001 per share (the "Common…
benzinga.com AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer Trial AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod)…- benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring…
benzinga.com Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $9 Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $10 to $9.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com AIM ImmunoTech To Present Pre-Clinical Data On Potential Role Of Its Lead Drug Ampligen For Ebola Virus Treatment AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases,…
benzinga.com AIM ImmunoTech Announcing $2.4M Registered Direct Offering Of 7.5M Shares At $0.325 Each. AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com AIM ImmunoTech Q1 EPS $(0.69) Down From $(0.05) YoY, Sales $22.000K Miss $100.000K Estimate AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.69) per share. This is a 1280 percent decrease over losses of $(0.05) per share from the same period last year. The company reported…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Nasdaq Jumps 200 Points; US Adds 115,000 Jobs In April US stocks rise as Nasdaq gains over 200 points, with tech leading. Nonfarm payrolls beat expectations but unemployment rate remains unchanged. Oil down 0.3%, gold up 0.8%, European and Asian markets…
benzinga.com AIM ImmunoTech Announces Final Primary Endpoint Report On Objective Response Rate Data From Phase 2 Trial Evaluating Ampligen, With Topline Results Indicating 50% Objective Response Rate, Including 21% Complete Responses AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ("UPMC") Phase…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday Top analysts changed outlook on top names. For complete view of all rating changes, see analyst ratings page. See others' views on stocks.- benzinga.com Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10 Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.
- benzinga.com Earnings Scheduled For March 24, 2026
benzinga.com What's Going On With AIM ImmunoTech Stock Friday? AIM ImmunoTech (AMEX: AIM) sees bullish momentum after final patent approval in Japan for its Ampligen-based oncology treatments.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Stock futures slightly lower, Alibaba falls after downbeat earnings, other stocks decline in pre-market trading.
benzinga.com Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4 results and issuing strong FY26 EPS guidance. Other gainers include LBGJ, ASNS, SVRN, SUNE, MDAI,…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Why Is AIM ImmunoTech Stock Gaining Today? AIM ImmunoTech stock surges after Japan fully approved a patent covering Ampligen with checkpoint inhibitors, strengthening its cancer-treatment IP portfolio.
benzinga.com Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results 
benzinga.com Dow Falls Over 150 POints; US Producer Prices Increase In February US stocks traded lower this morning with the Dow falling more than 150 points. Energy shares climbed while materials stocks fell. Producer prices rose.- benzinga.com AIM ImmunoTech Secures Full Japanese Patent For Ampligen Use With Checkpoint Inhibitors In Cancer Treatment AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen…
- benzinga.com AIM ImmunoTech Inks Deal With Thermo Fisher Scientific's PPD Clinical Research Business To Design AIM's Phase 3 Study In Use Of Ampligen Drug AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical…